Treace Medical Concepts Reports First Quarter 2026 Financial Results
Treace Medical Concepts, Inc. reported a first quarter 2026 revenue of $47.2 million, a 10% decrease from the previous year’s quarter. The net loss increased to $18.0 million, and adjusted EBITDA recorded a loss of $5.5 million. The company reaffirms its 2026 revenue guidance of $202 million to $212 million, amid challenges from product mix shifts and continues to focus on expanding its surgical treatment portfolio.
PONTE VEDRA, Fla., May 08, 2026 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the first quarter ended March 31, 2026.